Tissue factor pathway inhibitor 2 (TFPI2) is a potential serum biomarker for clear cell renal carcinoma.

Autor: Ito H; Department of Urology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan. hiroki22@yokohama-cu.ac.jp., Jikuya R; Department of Urology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan., Myoba S; Bioscience Division, Research and Development Department, Tosoh Corporation, Ayase, Kanagawa, Japan., Tatenuma T; Department of Urology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan., Noguchi G; Department of Urology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan., Ueno D; Department of Urology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan., Ito Y; Department of Urology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan., Komeya M; Department of Urology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan., Muraoka K; Department of Urology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan., Yao M; Department of Urology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan., Hasumi H; Department of Urology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan., Nakaigawa N; Department of Urology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan.; Department of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan., Makiyama K; Department of Urology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan.

Publikováno v: Scientific reports [Sci Rep] 2024 Nov 19; Vol. 14 (1), pp. 28639. Date of Electronic Publication: 2024 Nov 19.

Evaluation of PET/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP).

Autor: Nakaigawa N; Department of Urology, Yokohama City University, Yokohama City, Kanagawa 236-0004, Japan.; Department of Urology, Kanagawa Cancer Center, Yokohama City, Kanagawa 241-8515, Japan., Hasumi H; Department of Urology, Yokohama City University, Yokohama City, Kanagawa 236-0004, Japan., Utsunomiya D; Department of Diagnostic Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa 236-0004, Japan., Yoshida K; Department of Diagnostic Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa 236-0004, Japan.; Department of Radiology, Yuai Clinic Diagnostic Imaging, 1-6-2, Kita-shinyokohama, Kohoku-ku, Yokohama, Kanagawa 223-0059, Japan., Ishiwata Y; Department of Diagnostic Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa 236-0004, Japan., Oka T; Telix Pharmaceuticals Japan K.K., KRP #4 Building, 93 Chudoji-Awata-machi, Shimogyu-ku, Kyoto-shi, Kyoto, Japan., Hayward C; Telix Pharmaceuticals, 55 Flemington Road, North Melbourne, VIC 3051, Australia., Makiyama K; Department of Urology, Yokohama City University, Yokohama City, Kanagawa 236-0004, Japan.

Publikováno v: Japanese journal of clinical oncology [Jpn J Clin Oncol] 2024 Aug 14; Vol. 54 (8), pp. 873-879.

MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors.

Autor: Nagasaka H; Department of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan., Kishida T; Department of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan. kishidat@kcch.jp., Kouro T; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, 241-8515, Japan.; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Kanagawa, Japan., Igarashi Y; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, 241-8515, Japan.; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Kanagawa, Japan., Takebe S; Department of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan., Yamamoto S; Department of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan., Kondo T; Department of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan., Koizumi M; Department of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan., Terao H; Department of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan., Suzuki T; Department of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan., Nakaigawa N; Department of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan., Himuro H; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, 241-8515, Japan.; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Kanagawa, Japan., Wei F; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, 241-8515, Japan.; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Kanagawa, Japan., Sasada T; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, 241-8515, Japan. tsasada@kcch.jp.; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Kanagawa, Japan. tsasada@kcch.jp.

Publikováno v: International journal of clinical oncology [Int J Clin Oncol] 2024 Jun; Vol. 29 (6), pp. 832-839. Date of Electronic Publication: 2024 Apr 06.

Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma.

Autor: Nakaigawa N; Department of Urology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, 241-8515, Japan., Tomita Y; Department of Urology, Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuo-Ku, Niigata, 951-8510, Japan., Tamada S; Department of Urology, Bell Land General Hospital, 500-3 Higashiyama, Naka-Ku, Sakai City, Osaka, 599-8247, Japan., Tatsugami K; Department of Urology, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-Ku, Kitakyushu, 802-8561, Japan., Osawa T; Department of Renal and Genitourinary Surgery, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan., Oya M; Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan., Kanayama H; Department of Urology, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto-Cho, Tokushima, 770-8503, Japan., Miura Y; Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, 105-8470, Japan., Sassa N; Department of Urology, Aichi Medical University School of Medicine, Yazako-Karimata 1-1, Nagakute, Aichi, 480-1195, Japan., Nishimura K; Department of Urology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka, 541-8567, Japan., Nozawa M; Department of Urology, Kindai University Faculty of Medicine, 377-2 Onohigashi, Osakasayama-Shi, Osaka-Fu, 589-0014, Japan., Masumori N; Department of Urology, Sapporo Medical University School of Medicine, S1 W16, Chuo-Ku, Sapporo, 060-8543, Japan., Miyoshi Y; Department of Urology and Renal Transplantation, Yokohama City University Medical Center, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 326-0004, Japan., Kuroda S; Statistical and Quantitative Sciences, Data Science Institute, Research and Development, Takeda Pharmaceutical Company Limited, 1-1 Doshomachi 4-Chome, Chuo-Ku, Osaka, 540-8645, Japan., Kimura A; Oncology Therapeutic Area Unit for Japan and Asia, Takeda Pharmaceutical Company Limited, 1-1 Doshomachi 4-Chome, Chuo-Ku, Osaka, 540-8645, Japan. akiko.kimura1@takeda.com.

Publikováno v: International journal of clinical oncology [Int J Clin Oncol] 2023 Mar; Vol. 28 (3), pp. 416-426. Date of Electronic Publication: 2023 Jan 03.

Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor.

Autor: Nagasaka H; Department of Urology, Kanagawa Cancer Center, Yokohama, Japan., Takebe S; Department of Urology, Kanagawa Cancer Center, Yokohama, Japan., Yamamoto S; Department of Urology, Kanagawa Cancer Center, Yokohama, Japan., Kondo T; Department of Urology, Kanagawa Cancer Center, Yokohama, Japan., Terao H; Department of Urology, Kanagawa Cancer Center, Yokohama, Japan., Nakaigawa N; Department of Urology, Kanagawa Cancer Center, Yokohama, Japan., Kishida T; Department of Urology, Kanagawa Cancer Center, Yokohama, Japan.

Publikováno v: Case reports in oncology [Case Rep Oncol] 2023 Sep 25; Vol. 16 (1), pp. 1028-1032. Date of Electronic Publication: 2023 Sep 25 (Print Publication: 2023).